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Introduction: Renal dysfunction is a frequent complication after heart transplantation (HTx). It is
mainly a result of ischemic-reperfusion injury and/or the use of calcineurin inhibitors (CNIs).
Serum creatinine and glomerular ﬁltration rate (GFR) are widely used parameters for evaluation
of renal function. However, serum creatinine is not accurate indicator, especially when kidney
function changes. In our study, we focused on the assessment of microalbuminuria, cystatin C,
lipocalin-2 (NGAL) and alpha-1-microglobulin (α-1M).
Aim: To describe the association between the measured biomarkers and renal functions during 6
months of follow-up.
Methods: We studied 77 patients undergoing HTx (mean age 50.1±12.8, 64 males/13 females),
using serial blood and urine sampling up to 6 months after the transplant. Serum cystatin C and
NGAL were estimated by automated immunoanalysis (Abbott, Architect), α-1M was evaluated
using nephelometry (Beckman, Immage). Estimation of glomerular ﬁltration rate (eGFR) was
based on serum concentrations of cystatin C. ACR ratio (g/mol) was calculated as the ratio of
urinary albumin and creatinine.
Results: Renal dysfunction evaluated using the serum concentrations of cystatin was associated
with increased concentrations of α-1M and NGAL. Elevated urinary concentration of α-1M on day
30 and during month 6 correlated with increased serum concentration of cystatin C during
month 6 after HTx (po0.05 and po0.001, respectively). Elevated urinary concentration of NGAL
on day 3 after HTx was associated with increase in the serum concentration of cystatin during
month 6 after HTx (po0.01), however, no correlation was found with cystatin C early after
surgery.
Patients with impaired renal function (necessity to use an elimination method)showed
signiﬁcantly higher serum NGAL on day 3 after HTx) than in patient without renal impairment
(po0.01). The value of albumin/creatinine ratio (ACR) gradually normalized during the follow-up,
increased ACR being seen in only 16% of patients during month 3 after HTx. On the contrary,
the urinary concentration of α-1M remains elevated during month 3 in 56% of patients. As for
the association between ACR and α-1M, correlation coefﬁcients were 0.372 for all paired valuesh Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
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c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 6 4 – e 3 6 9 e365(n¼510, po0.0001). Serum cystatin C concentration values above 1.5 mg/L on day 10 after HTx
were associated with worse prognosis (increased risk of death, po0.05).
Conclusion: The study has shown that evaluation of α-1M and NGAL on day 3 after the
transplantation can predict the renal function 6 months after HTx. Increased serum cystatin C
concentration on day 10 after HTx is associated with worse prognosis.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights
reserved.
.1. IntroductionRenal dysfunction is a frequent complication after heart trans-
plantation (HTx). The most common cause of renal failure in the
early postoperative period is an ischemic-reperfusion damage [1].
Extracorporeal circulation and high surgical risk can result in
acute kidney injury (AKI) in some cases. Serum creatinine con-
centration and glomerular ﬁltration rate are used for evaluation of
renal functions in everyday clinical practice. These traditional
markers, however, do not allow for detection of initial stages of
renal dysfunction when the deterioration of glomerular ﬁltration
has not yet occurred but when proteins from damaged tubular
cells can already be found in urine. Later after transplantation,
renal dysfunction can also be caused by nephrotoxicity of
calcineurin inhibitors [2,3]. The mechanism of chronic nephro-
pathy development has not yet been fully elucidated but it
involves the activation of renin–angiotensin system, increased
production of endothelin 1 and impaired nitric oxide synthesis,
increased expression of transforming growth factor beta (TGF β).
Long-term vasoconstriction results in structural changes in the
kidney, manifesting by tubular atrophy, interstitial ﬁbrosis and
focal hyalinosis of afferent arterioles [4,5]. The development of
renal dysfunction is enhanced by other factors such as preexisting
renal disease, dyslipidemia, hypertension, diabetes mellitus,
advanced age or weight [6]; the history of ischemic heart disease
is associated with a 2-fold increase in the risk of renal dysfunction
following HTx [7]. Most patients used of CNIs show some degree
of renal damage as soon as 6 months after heart HTx [8,9,10]
while 5–10% reach the end stage renal disease [11,12]. Renal
dysfunction after the transplantation is associated with increased
morbidity and mortality [13].
The use of biomarkers in the evaluation, monitoring and prog-
nostics in patients with kidney damage continues to evolve. Cystatin
C, alpha-1-microglobulin(α-1M) and neutrophil gelatinase-associated
lipocalin (NGAL) are considered „novel“ markers of kidney injury.
Cystatin C is a protein, one of cysteine protease inhibitors, freely
ﬁltrated in the glomerules, resorbed and completely degraded by the
cells in the proximal tubule. Plasmatic concentration of cystatin thus
depends fully on the glomerular ﬁltration rate (GFR), which makes
cystatin C an excellent marker of glomerular ﬁltration [14]. It is not
affected by age, sex, inﬂamation or muscle weight and it does not
bind to proteins. Alpha-1-microglobulin is a tubular protein produced
in the liver, freely ﬁltrated in the glomerules and 99% of its volume is
reabsorbed from the plasma ultraﬁltrate via megalin receptor in the
proximal tubule. Elevated urinary concentrations are a result of
impaired reabsorption in the proximal tubule, thus yielding α-1M
an early marker of proximal tubule damage [15]. NGAL (neutrophil
gelatinase-associated lipocalin, also known as lipocalin-2) is a small
protein found in neutrophils and in other cells/tissues. Its production
in the renal tubules is markedly increased during the early phase ofischemic or toxic injury. NGAL is not substantially inﬂuenced by
diuretics or volume depletion. It is considered a highly sensitive and
speciﬁc marker of early tubular damage [16].
The aim of our work was to evaluate the association between
measured markers and renal functions during the 6 months of
follow-up in heart transplant recipients.2. Methods
Seventy seven patients (64 men and 13 women) undergoing HTx,
with a mean age of 50.1±12.8 yr and median age 54 yr (22–74 yr)
were enrolled in the prospective study. All patients were
followed-up for 6 months. Indication for HTx were non-
ischemic (n¼46) and ischemic (n¼30) cardiomyopathy and
congenital heart disease in 1 patient.
2.1. Immunosuppression
All patients received an induction therapy with thymoglobuline.
Tacrolimus and mycophenolate were administered according to
the protocol. The concentration of tacrolimus was kept in the
range of 10–15 µg/L. Mycophenolate was discontinued on day 30
in 2 patients because of leucopenia; by month 3, the number of
patients in whom this drug had to be discontinued raised to 7
(leucopenia being the reason in 6 and gastrointestinal disorders in
1 patient). During month 6 after HTx, 5 patients discontinued
mycophenolate.
2.2. Monitoring of acute rejection
During the ﬁrst 6 months, all patients underwent 7 endomyo-
cardial biopsies according to the protocol.
2.3. Monitoring of renal functions
Blood and urine samples were evaluated using standard laboratory
methods. Serum concentration of cystatin was measured on days 0,
1, 7, 10, 30þduring months 3 and 6 after HTx. Urinary concentration
of α-1M was measured before the operation and on days 0, 1, 3, 10
and 30þduring months 3 and 6 after HTx, urinary concentration of
NGAL measurements were done 1–3 h following HTx and then on
days 1 and 3. Serum concentration of creatinine was assessed
enzymatically. Serum concentrations of cystatin C and urinary
concentrations of albumin and NGAL were evaluated using auto-
mated immunoanalysis (Abbott, Architect), α-1M was measured
nephelometrically (Beckman, Immage, normal values below
12.5 mg/L). Estimation of glomerular ﬁltration rate (eGFR) was made
from the serum concentration of cystatin C. Microalbuminuria was
quantiﬁed using albumin/creatinine ratio (ACR) with normal values
below 2.5 g/mol for men and 3.5 g/mol for women.
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Statistical calculations were done using MedCalc software, version
11.6.1.0. Non-parametric Kruskal–Wallis test was used to test the
hypothesis about equality of independent populations, correlation
coefﬁcient was also calculated as non-parametric (Spearman's
coefﬁcient), paired values were compared using Wilcoxon's test.
Values exceeding the 95% probability limits (po0.05) were
considered statistically signiﬁcant. Calculation of the risk of
mortality after HTx was based on a logistic regression model,
i.e. on points attributed to individual variables and their values
(age, bilirubin, eGFR, dialysis, female sex, etiology of heart failure,
infections, artiﬁcial pulmonary ventilation and mechanical heart
support)—so called IMPACT score. Survival was evaluated with the
Kaplan-Meier method.3. Results
In total, 77 de novo heart transplant recipients were enrolled.
The baseline characteristics of the study population are summar-
ized in Table 1. Renal functions during month 6 following HTx
were assessed in 50 patients. Median values of the measured
biomarkers (25.–75. percentiles) are given in Table 2. Immuno-
suppressive prophylaxis was applied according to the protocol—
all patients received tacrolimus and prednisone, mycophenolate
was given to 93% of patients. During the ﬁrst month following
HTx, 2 patients were treated for acute cellular rejection and 1
patient for severe humoral rejection. During month 6 after HTx, 3
cases of acute cellular rejection – with severe hemodynamic
consequences in one patient – were treated. Five patients died
during the follow-up (3 deaths were caused by infectious com-
plications, 1 death by multiorgan failure and 1 death was sudden).
Renal dysfunction evaluated according to the serum concen-
tration of cystatin was associated with increased concentrations
of α-1M and NGAL. Elevated urinary concentration of α-1M on day
30 and during month 6 correlated with increased serum concen-
tration of cystatin C during month 6 after HTx (po0.05 and
po0.001, respectively), Fig. 1. Elevated urinary concentration of
NGAL on day 3 after HTx was associated with increased serum
concentration of cystatin C during month 6 after HTx (po0.01):
Fig. 2; however, no correlation was found with cystatin C earlyTable 1 – Baseline characteristics of the study population.
n¼77
Age (yr) 50.1±12.8
Men/women [No. (%)] 64 /13 (83.1/16.9)
Height (cm) 174.3±14.6
Weight (kg) 77.9±18.2
Creatinine prior to HTx (μmol/L) 103.9±35.2
ICD or BIV ICD prior to HTx [No. (%)] 49 (63. 6)
Mechanical support prior to HTx [No. (%)] 32 (41.5)
Additive EuroSCORE 11.5±3.2
Logistic EuroSCORE 32.3±19.9
ECC duration (min) 147.1±41.2
IT (min) 144.3±55.5
Abbreviations: ECC—extracorporeal circulation, IT—ischemic time
(interval between the application of the aortic cross-clamp in
the donor during harvesting and removal of the aortic clamp in the
recipient during implantation).after surgery (immediately after HTx and during the ﬁrst 2 days).
Patients with signiﬁcant renal dysfunction (AKI requiring the use
of elimination method) had signiﬁcantly higher concentrations of
NGAL on day 3 after HTx than patients without renal injury
(po0.01), Fig. 3. Microalbuminuria (or ACR ratio) provides differ-
ent information than does the α-1M value. The value of ACR ratio
gradually normalized during the follow-up; during month 3,
increased ACR values were seen in 16 patients only. On the
contrary, increased urinary concentrations of α-1M during month
3 were still noted in 56% of patients. As for the association
between ACR and α-1M, correlation coefﬁcients were 0.372 for all
paired values (n¼510, po0.0001). Increased serum concentration
of cystatin C (above 1.5 mg/L) on day 10 after HTx was associated
with worse prognosis (increased risk of death, po0.05), Fig. 4.4. Discussion
In this study, we were trying to describe the relationships between
cystatin C, alpha-1-microglobulin and NGAL on one hand and renal
functions on the other, as seen during 6 months of follow-up. Renal
functions are usually assessed using serum creatinine concentration
in everyday clinical practice. The concentration of creatinine depends
on age, sex and muscle volume. Glomerular ﬁltration rate assessment
is more complicated in outpatients and its value is mostly being
estimated based just on the serum creatinine concentration. None of
the equations for the estimation of glomerular ﬁltration rate from the
serum creatinine concentration: MDRD (Modiﬁcation of Diet in Renal
Disease), CKD-EPI (Chronic Kidney Disease), Lund-Malmö and Mayo
Clinic eliminates the disadvantage of creatinine measurement [17].
We estimated the glomerular ﬁltration rate (eGFR) using
cystatin C—this method is easily available and requires only one
blood sample without the need to collect urine. It is especially
useful in patients whose muscle volume changes greatly during the
follow-up. The other advantages of cystatin C concern its indepen-
dence on age and inﬂammation and the fact that it does not bind to
proteins. Numerous studies and meta-analyses comprising 4492
samples have shown that serum concentration of cystatin C is a
better marker of GFR than serum concentration of creatinine [18].
Cystatin C is as a prognostic marker of cardiovascular risk in
some studies. The study by Keller et al. [19] involving 2162 patients
with ischemic heart disease has shown that cystatin C was also a
prognostic marker of cardiovascular mortality beside the classical
risk factors. In a Scandinavian paper [20], the serum concentration of
cystatin higher than 1.55 mg/L in patients suffering from acute heart
failure was associated with decreased 1-yr survival. In a study with
79 pediatric patients after HTx, the evaluation of cystatin C and
NGAL resulted in 2–3 times more common detection of renal
dysfunction than the classical evaluation of GFR [21]. Kniepeiss
[22] concluded that cystatin C was an early prognostic marker of
renal dysfunction in patients more than 5 yr after HTx and it was
demonstrated that serum cystatin C was a better prognostic marker
of renal dysfunction than conventionally assessed creatinine.
We have provided evidence about the association between
increased serum concentration of cystatin C and worsened prognosis
of patients after HTx. Patients with serum concentrations of cystatin
C above 1.5 mg/L on day 10 after HTx were characterized by worse
survival (po0.01). However, similar association was not demon-
strated for patients 30 days after HTx (p¼0.074). Further study will
be necessary to conﬁrm these results.
Table 2 – Biomarkers measured during 6 months after HTx, Biomarker values are expressed as median (25th–75th
percentile).
Prior to
HTx
Day 0 Day 1 Day 3 Day 10 Day 30 Month 3 Month 6 P value
ACR 2.0 13.0 5.0 3.1 1.8 1.2 1.3 1.35 *po0.0001
(g/mol) (1.2–4.3) (5.5–27.5) (2.2–10.8) (1.6–8.0) (0.8–3.8) (0.6–3.4) (0.6–2.1) (0.7–3.1)
S-cystatin C 1.31 1.43 1.44 1.29 1.25 1.36 n.s.
(mg/L) (1.1–1.8) (1.1–2.0) (1.2–1.9) (1.1–1.6) (1.1–1.6) (1.2–1.7)
S-creatinine 114.8 117.0 71.8 76.4 90.9 100.9 n.s.
(mol/L) (94.5–
136.3)
(85.2–
147.8)
(60.0–
88.6)
(63.2–
87.2)
(76.0–
110.2)
(88.3–
123.8)
U-α-1M 15.3 77.7 46.0 22 36.4 25.8 16.2 15.4 *po0.0001
(mg/L) (5.5–32.8) (53.0–
187.0)
(21.8–
86.8)
(7.715–
57.6)
(24.6–
66.2)
(11.1–
48.1)
(5.6–32.8) (6.3–38.1)
U-NGAL 598.4 55 17.2 **po0.0001
(g/L) (70.2–
2445.4)
(20.7–
243.2)
(6.7–35.1)
eGFRCystC 0.9 1.01
(ml/s) (0.7–1.2) (0.7–1.1)
MDRD-4 1.22 1.08
(ml/s/1.73m2) (0.9–1.6) (0.9–1.3)
Abbreviations: ACR, Albumin/creatinine ratio; S-cystatin C, Serum cystatin C; S-creatinine, Serum creatinine; U-α-1M, Urinary alpha-1-microglobulin; U-
NGAL, Urinary neutrophil gelatinase-associated lipocalin; eGFRCystC, estimation of glomerular ﬁltration rate (eGFR) was made from the serum
concentration of cystatin C; MDRD-4, Modiﬁcation of Diet in Renal Disease formula; MDRD4¼2.92 (S-creatinine0.0133) −1.154 age −0.203 [0.742 if
female].
 po0.0001 (difference between day 0 and month 6).
 po0.0001 (difference between day 0 and day 3).
Fig. 1 – Alpha 1-microglobulin (α-1M), Increased urinary level of α-1M ≥12 mg/l at 1-st and 6-th month was associated with
increased serum cystatin C at 6th month after HTx. *po0.05 and ***po0.001.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 6 4 – e 3 6 9 e367Microalbuminuria (ACR) is one of the markers of glomerular
lesion while alpha-1-microglobulin is a marker of tubular injury.
These two markers cannot replace one another, as documented by
a relatively low – albeit statistically signiﬁcant – correlation
coefﬁcient between them.
The assessment of α-1M as an early marker of proximal tubule
injury in patients after HTx has not yet been evaluated systematically.
The experience with α-1M assessment is scarce and rather concerns
acute renal injury after cardiac surgeries [23], most often following an
aortocoronary bypass. The interpretation of results is not quite simple
since concentrations of this low-molecular weight protein have
diurnal variations and change with age; urinary concentrations are,
however, stable. The study by Heise [24] has shown an increase in α-
1M concentrations on days 1 and 2 following the operation. We have
made repeated assessments of biomarkers and found out thatelevations of α-1M ≥12mg/L on day 30 and during month 6 correlate
with increased concentrations of cystatin C 6 months after HTx.
As mentioned above, the identiﬁcation of risk of renal injury
using changes of serum creatinine concentrations is not enough
sensitive and is late. Markers of tubular dysfunction have been
evaluated more and more often lately, most data being available for
the evaluation of NGAL. NGAL predicts the deterioration of renal
functions in acute heart failure—a ﬁnding conﬁrmed by the GAL-
LANT trial, in which patients with NGAL above 100 μg/L plus BNP
above 330 ng/L had the worst prognosis [25]. The predictive value of
NGAL is similar in chronic heart failure [26]. Again, most works
dealing with the evaluation of NGAL concern post-cardiac surgery
patients [27]. Especially the extracorporeal circulation use is asso-
ciated with about 30% risk of AKI development. Not only ischemia
and reperfusion but also inﬂammatory changes, hemodynamic
Fig. 2 – Neutrophil gelatinase-associated lipocalin (NGAL),
Elevated urinary level of NGAL at 3-rd post-transplant day
was associated with increased serum cystatin C at six
month after HTx, **po0.01.
Fig. 3 – Neutrophil gelatinase-associated lipocalin (NGAL) in
acute kidney injury (AKI), Elevated urinary NGAL at 3-rd
post-transplant day was associated with AKI (use of the
elimination method), **po0.01.
Fig. 4 – Effect on survival of elevated serum cystatin C,
Kaplan-Meier curves for patients with normal serum
cystatin C at 10-th day after HTx (upper line, cystatin
Co1.5 mg/l) and patients with elevated serum cystatin C at
10-th day after HTx (lower line, cystatin C≥1.5 mg/l).
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 6 4 – e 3 6 9e368factors (non-pulsatile ﬂow, microembolizations), exogenous and
endogenous toxins, free hemoglobin, oxidative stress and other
factors are responsible; the duration of extracorporeal circulation
use, however, is crucial.
Assessment of NGAL after HTx was already discussed in several
papers—they conﬁrmed the elevation of NGAL immediately after HTx,
especially in patients with additional risk factors such as hypertension
or diabetes [28,29]. The quality of these data is limited by the fact that
urine samples for NGAL assessment were mostly collected just on day
1 or 2 after HTx. However, detailed results concerning NGAL in our
population did not show only a steep elevation of NGAL immediately
after the surgery with a decrease on day 2; in some patients, NGAL
concentrations did not rise before day 2, which was the reason why
we added NGAL evaluation on day 3 after HTx. According to this
protocol, we found a signiﬁcant association between the elevated
concentration of NGAL on day 3 and increased serum concentration of
cystatin during month 6 after HTx. Elevated concentration of NGAL
immediately after HTx and on day 1 lacked this predictive value.
Patients with signiﬁcant renal dysfunction (requiring the use of
elimination method following the HTx) in our population hadsigniﬁcantly higher NGAL concentrations (median 70.3 μg/L; 1st to
4th quartile range 38.1–99.9 μg/L) than patients not requiring elim-
ination method use (median 14.9 μg/L; 1st to 4th quartile range 6.7–
26.7 μg/L; po0.001). The above results show that NGAL is a perspec-
tive marker of acute renal injury with high sensitivity and speciﬁcity.
Increase in NGAL concentrations during the early post-surgical period
can be noted 1–2 days before the elevation of serum creatinine.
Both assessments—NGAL informing about tubular damage and
cystatin C about disordered ﬁltration—are important markers of renal
injury since they react before the elevations of creatinine and urea
concentrations occur. The prompt availability of this tests (using of
automated analyzers in laboratory) can help therapeutic decision-
making and provide more intensive medical care to this patient
group. Unfortunately, NGAL lacks organ speciﬁcity: it is produced by
neutrophils, renal cells, hepatic cells, and by the myocardium. Thus,
even the results of studies published so far have to be evaluated with
the fact in mind that they were carried out in exactly deﬁned
populations (patients with acute of chronic heart failure, following
aortocoronary bypass, etc.); more precise evaluations and deﬁnitions
of values characteristic of renal injury will require additional data
obtained with more heterogeneous groups.5. Conclusion
The results of our study have shown an association between
serum concentration of cystatin C and markers of tubular injury.
The assessment of α-1M and NGAL early after transplant proce-
dure not only helps the early diagnostics of acute renal injury but
it can also predict renal functional status 6 month after HTx.
Cystatin C can be viewed as a cardiorenal biomarker. We found
that elevated serum concentration of cystatin C on day 10 post-
transplantation was associated with worse prognosis. Further
follow-up will be required to understand the dynamics of “novel”
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 6 4 – e 3 6 9 e369biomarkers and the possibilities of their clinical use in the
evaluation of renal dysfunction after HTx.Acknowledgments
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